Last reviewed · How we verify
XKDCT225
At a glance
| Generic name | XKDCT225 |
|---|---|
| Sponsor | Shenzhen Celconta Life Science Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XKDCT225 CI brief — competitive landscape report
- XKDCT225 updates RSS · CI watch RSS
- Shenzhen Celconta Life Science Co., Ltd. portfolio CI